Compare DIOD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIOD | NUVB |
|---|---|---|
| Founded | 1959 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 1995 | N/A |
| Metric | DIOD | NUVB |
|---|---|---|
| Price | $61.40 | $4.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $73.50 | $11.22 |
| AVG Volume (30 Days) | 480.7K | ★ 4.8M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.53 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.51 | $182.76 |
| Revenue Next Year | $10.05 | $91.83 |
| P/E Ratio | $44.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.93 | $1.57 |
| 52 Week High | $81.71 | $9.75 |
| Indicator | DIOD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 33.85 |
| Support Level | $49.45 | $3.92 |
| Resistance Level | $81.71 | $5.73 |
| Average True Range (ATR) | 3.02 | 0.35 |
| MACD | -1.18 | -0.07 |
| Stochastic Oscillator | 5.11 | 25.27 |
Diodes Inc is a manufacturer and supplier of high-quality application-specific products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. It serves the customer electronics, computing, communications, industrial, and automotive markets. The Company's products include diodes; rectifiers; transistors; MOSFETs; GPP bridges; GPP rectifiers; protection devices; function-specific arrays; single gate logic; amplifiers and comparators; Hall-effect and temperature sensors; and power management devices, including LED drivers, AC-DC converters and controllers, DC-DC switching and linear voltage regulators, voltage references along with special-function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.